Federal regulators are confronting a new twist in drug development: manufacturers that include software with the medicine to prod patients to take pills as directed, manage side effects or track how well a treatment works. The apps could boost the drugs' clinical value and provide a more personalized approach to managing chronic conditions such as depression, obesity and musculoskeletal problems.
